“The weirdness of a generic drug company offering a generic version of its own branded but off-patent product is a signal that something is wrong,” he said in a statement. “In short, today’s announcement is just one more convoluted mechanism to avoid plain talk, admit to price gouging and just cut the price of EpiPen.”
While brand-name drug companies sometimes start selling so-called authorized generic versions of their own products, it is usually to undercut an outside generic competitor. In this case, Mylan faces no immediate generic threat.
Also read: 3D printers are now able to print body parts